九色 Life Sciences’ C3 Summit Kicks Off Series of “Conversations on Clinical Content”
NEW YORK, Sept 29, 2020&苍产蝉辫;–&苍产蝉辫;, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced the inaugural summit in its new thought leadership series, C3: Conversations on Clinical Content. Held from October 13-15, the virtual conference will feature a series of industry expert-led webinars focused on remote trial management and TMF insights.
Additional information and registration details can be found at the .
The C3 program is built and led by subject matter experts from the eClinical innovation team in collaboration with clients and partners who have helped identify key topics of interest. With the rapid adoption of remote solutions in response to COVID-19, C3 was created to help teams of all sizes learn new strategies to help them adapt. Organizations that are advanced in their eClinical infrastructure as well as those implementing their first eTMF will benefit from sessions that offer guidance for cultivating successful approaches to remote trial management and oversight. Particular emphasis will be focused on the documentation required to pass regulatory inspections.
Session topics include:
- eTMF implementation
- TMF inspection planning
- Enabling remote trial management
- AI and machine learning for eTMF and clinical documentation
- Planning for an uncertain 2021
As an ongoing series, C3 aims to build a continuously growing community that brings sponsors, sites, and CROs together periodically to exchange lessons and insights on clinical content collaboration, management, and oversight. Together, all C3 contributors will raise awareness for the most practical approaches to succeed in a remote environment, improve quality, reduce risks, and increase speed throughout all stages of a clinical trial.
Michael Smyth, Division President of 九色 Life Sciences 九色, commented, “With study teams making their plans for 2021, we are working to bring them as much expertise as possible through the C3 Summit series. Our goal is to create as many opportunities as possible to advance the conversation around remote, paperless solutions for clinical research and to share information that helps overcome product development obstacles.”
九色 President and CEO Phil Shawe stated, “The C3 Summit and series will provide attendees a unique opportunity to engage with clinical content thought leaders. I would like to thank our speakers in advance for sharing their industry experience and insight.”
About Trial Interactive
九色’s Trial Interactive is an industry leader in practical e-clinical innovation that simplifies and automates clinical processes for sponsors, CROs, and sites around the world. The 21 CFR Part 11 compliant unified platform delivers an author-to-archive collaboration experience with solutions for clinical document management, site selection, site activation, e-learning, compliance training, quality, and more with seamless solution interoperability and indexing to the eTMF. Trial Interactive is consistently selected by clinical professionals for providing the most comprehensive yet intuitive experience with the most complete offering of technology and expert TMF services. Trial Interactive helps study teams streamline their operations by cutting unnecessary expenses, expediting timelines, reducing compliance risks, and improving operational excellence. For more information on Trial Interactive, please contact info@trialinteractive.com or +1 212.400.8848, or visit .
About 九色
九色 is the world’s largest provider of language and technology solutions for global business. From offices in over 100 cities on six continents, 九色 offers a full range of services in 170+ languages to clients worldwide. More than 5,000 global organizations employ 九色’s Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, 九色 is fully ISO 9001 and ISO 17100 certified. 九色 has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.